中國的醫療改革 是由出版商Business Insights在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 112 價格從美金3835起跳。
歷史上中國是醫療患者的自我負擔支出極為大的國家。可是，2001年60％的自我負擔率，隨著社會保險制度的普及2008年下降到40％。國內人口到2020年為止預計增加8500萬人，由於85％屬於60多歲的世代，心臟疾病，癡呆症，糖尿病，肥胖症之外的高齡和生活習慣的疾病的劇增預計將使醫療市場成長。
本報告提供中國的人口階層，網羅該國醫療改革計劃的詳細內容資訊醫藥品廠商，使用者，醫護人員各種的觀點提供，改革內容及相關利益者的意義的評估最新的評估·分析資訊，總體的醫療基本設備，及醫療改革需求概要，資訊由中國醫院管理者23人的意見交流所構成，為您概述為以下內容。
摘要整理
- 中國人口的變遷
- 中國的醫療制度與改革需求
- 中國的醫療改革
- 相關利益者的改革的意義
關於作者
中國人口的變遷
- 摘要
- 簡介
- 人口增加
- 老化的人口
- 治療的重點變更
- 中產階級的崛起與支出能力的增加
- 都市化
中國的醫療制度與改革需求
- 摘要
- 簡介
- 中國的醫療史
- 法律規範和監督機構
- 衛生署
- 國家食品藥品監督管理局
- 人力資源社會保障部
- 國家發展改革委員會
- 其他的醫療相關行政機關
- 新藥法規
- 新藥登記手續
- 藥物回收
- 保健·醫療機關
- 都市區的醫療
- 地方的醫療
- 醫院醫療的差距
- 都市區醫療與地方醫療
- 國內的藥價設定和醫療報酬
- 報酬的藥物核准
- 中藥
中國的醫療改革
- 摘要
- 國民全部保險
- 基本的醫療保險
- 城市居住者的基本的醫療保險
- 地方居住者的新工會醫療保險
- 民間保險
- 健康保險計劃的評估
- 藥價制度改革
- 必需藥品一覽
- 國家指定報酬對象藥物一覽
- 醫院改革
- 擴大的地區診療所數
- 醫院的財務改革
相關利益者的改革的意義
- 摘要
- 簡介
- 醫藥品廠商
- 醫院
- 開發受託機關
- 醫療設備廠商
- 民間健康保險公司
- 醫療資訊科技企業
- 評估與結論
附錄
- 調查範圍
- 調查方法
- 用語·語彙
- 參照資料
- 問卷調查回答
Description
INTRODUCTION
This report gives an overview of China's demographics, overall healthcare infrastructure, and the need for healthcare reforms. It provides detailed coverage of China's healthcare reform plans from the viewpoint of pharmaceutical companies, payers, and healthcare providers. Reforms and implications for various stakeholders are assessed and comments from 23 managers at Chinese hospitals included.
FEATURES AND BENEFITS
- Learn how healthcare is being reformed in China and the effects on various industry stakeholders.
- Develop strategies for successful market penetration in China.
- Understand the regulatory structures which affect how drugs are approved and reimbursed in China.
- Gain insights about the effects of reform from a Scrip Business Insights survey of 23 managers at Chinese hospitals.
- Evaluate the importance of tier 2 and 3 cities in China's pharmaceutical market.
HIGHLIGHTS
Historically, China had a very high out-of-pocket expenditure on healthcare. However, the proportion of out-of-pocket expenditure on healthcare dropped from 60% in 2001 to 40% in 2008 due to the increasing coverage of social health insurance schemes.
China's population will increase by 85m people between 2010 and 2020. 85% of this will be accounted for by an increase in the population of over 60s, which will prompt growth in markets for cardiovascular diseases, dementia, and other age-linked conditions. A sharp rise in lifestyle diseases such as diabetes and obesity is also underway.
Reforms are set to present opportunities for pharma companies, CROs, medical device manufacturers, and private health insurance providers. Healthcare IT is also set for a boost, as the government begins to invest in electronic health records.
YOUR KEY QUESTIONS ANSWERED
- How is healthcare provision in China changing, and how can pharma companies capitalize on this?
- How will healthcare reform in China affect CROs and clinical research?
- What are the opinions of Chinese hospital managers on the effects of reform?
- What are the advantages and disadvantages for a company to have a product listed on the national drug reimbursement lists?
- How will medical device manufacturers and private health insurance providers be affected by healthcare reforms?
Table of Contents
Executive Summary
- China's changing population
- China's healthcare system and the need for reform
- Healthcare reform in China
- Implications of reforms for stakeholders
About the author
China's changing population
- Summary
- Introduction
- Increasing population
- Aging population
- Change in therapeutic focus
- The rise of the middle class and increase in spending power
- Urbanization
- Maximizing the opportunity of smaller city markets
China's healthcare system and the need for reform
- Summary
- Overview
- History of Chinese healthcare
- Regulatory structure and government departments
- The Ministry of Health
- The State Food and Drug Administration
- Ministry of Human Resources and Social Security
- National Development and Reform Commission
- Other healthcare related agencies
- New drug regulation laws
- New drug registration procedures
- Drug recalls
- Organization of healthcare and the hospital system
- Urban healthcare
- Rural healthcare
- Differences in hospital healthcare
- Urban healthcare and rural healthcare
- Pricing and reimbursement in China
- Approving drugs for reimbursement
- Traditional Chinese Medicine
Healthcare reform in China
- Summary
- Universal medical insurance
- Basic Medical Insurance
- Urban Resident Basic Medical Insurance
- New Rural Cooperative Medical Insurance
- Private insurance
- Assessment of health insurance programs
- Drug pricing reform
- Essential Drug List
- The National Reimbursement Drug List
- Hospital reform
- Increasing the number of community health clinics
- Reform of hospital finance
Implications of reforms for stakeholders
- Summary
- Introduction
- Pharmaceutical companies
- Hospitals
- Selected responses to three qualitative survey questions
- Private hospital opportunities
- Contract research organizations
- Medical device companies
- Private health insurance companies
- Healthcare IT companies
- Assessment and conclusion
Appendix
- Scope
- Methodology
- Glossary/Abbreviations
- References
- Company press releases
- Informa products
- Questionnaire responses
- Research procedure
- Detailed questionnaire responses
